Is a p53-Regulated Inhibitor of G2/M Progression
Heiko Hermeking(German Cancer Research Center), Bert Vogelstein(Johns Hopkins University), Christoph Lengauer(Blueprint Medicines (United States)), Kenneth W. Kinzler(Johns Hopkins University), Tong‐Chuan He(Northwestern University), Kornélia Polyák(Dana-Farber Cancer Institute), Lin Zhang(Mudanjiang Medical University), Sam Thiagalingam(Boston University)
Cited by 1,243
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k